Ken Song, RayzeBio CEO

With fresh $160M, Rayze­Bio plots sprint through the clin­ic for lead ra­dio­phar­ma­ceu­ti­cal pro­gram — build­ing on No­var­tis' suc­cess

Ever since its launch in 2020, Rayze­Bio has talked at length about build­ing a plat­form com­pa­ny to ful­fill the po­ten­tial that ra­dio­phar­ma­ceu­ti­cals hold — with sev­en ac­tive pro­grams to boast. But it’s stayed mum about what those pro­grams ac­tu­al­ly are, in­stead stick­ing to up­dates about new fund­ing, hires or part­ner­ships.

That’s by de­sign, ac­cord­ing to CEO Ken Song. The for­mer Ven­rock VC and se­r­i­al biotech en­tre­pre­neur want­ed to make sure that he had a re­al busi­ness case be­fore be­com­ing more vis­i­ble.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.